Kornimate/medical-research-clean huggingface dataset:
effects of digital pelvic floor muscle training in patients with multiple sclerosis having lower urinary tract symptoms

Conditions: Lower Urinary Tract Symptoms

Summary: the aim of this study was to investigate the effects of digital pelvic floor muscle training and lifestyle recommendations in patients with multiple sclerosis having lower urinary tract symptoms.

multiple sclerosis (ms) is an autoimmune, neurodegenerative disease of the central nervous system. lower urinary tract symptoms (luts) are very common in ms. pelvic floor muscle training (pfmt) is one of the first-line choices for the conservative treatment of luts. according to our knowledge, no study has investigated the effects of digital pelvic floor muscle training and lifestyle recommendations in ms having luts, yet.

Eligibility criteria:
inclusion criteria: * having a diagnosis of ms and having at least two of the lower urinary symptoms * not having an attack in the last 1 month, * no change in medical treatment in the last 3 months * "expanded disability status scale-edss" score is less than 6.5 * not having any cognitive problems that would hinder cooperation and understanding * those who use digital devices such as computers, laptops, smartphones and tablets * volunteering to participate in the study exclusion criteria: * pregnancy status * active urinary tract infection * another neurological disease that can cause incontinence * a history of malignancy * prostate surgery * those with missing evaluation parameters * those who do not regularly participate in treatment programs

Keywords: lower urinary tract symptoms multiple sclerosis pelvic floor muscle training
qt variability pre and post cardioversion

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to learn whether the chemicals in the blood and urine are different when the heart is atrial fibrillation compared to normal sinus rhythm.

atrial fibrillation variably activates the renin-angiotensin-aldosterone system (raas), stimulates the sympathetic nervous system, generates oxidant stress, produces natriuretic peptides, and increases ventricular rate. these are interrelated responses and the extent to which these or other pathophysiologic responses determine qt interval during and after atrial fibrillation (af) is unknown. in this study, the qt variability is related to those potential markers in patients with af undergoing elective dc-cardioversion.

Eligibility criteria:
inclusion criteria: * at least 21 years of age * scheduled to undergo an elective dc-cardioversion of atrial fibrillation or atrial flutter at vanderbilt university medical center exclusion criteria: * undergoing emergent dc-cardioversion of atrial fibrillation for hemodynamic instability * undergoing dc-cardioversion for post-cardiac surgery * dual chamber pacemakers

Keywords: atrial fibrillation cardioversion direct current cardioversion qt interval
effect of body suspension and tilting exercises in parkinson's disease

Conditions: Parkinson Disease

Summary: this study evaluates the effect of body suspension and tilting exercises (performed in chordata apparatus) on the balance and mobility of subjects with parkinson disease. half of patients will perform the exercise protocol while the other half will receive passive muscle stretching and maintain the usual routine.

body suspension and tilting exercises performed in the chordata equipment might be an effective option to improve trunk muscles activation and to facilitate functional balance and mobility control in parkinson's disease (pd). to evaluate this hypothesis, subjects will be randomized into control group or intervention group. intervention group will receive 30-minute session of body suspension and tilting exercises on the chordata equipment (pi: 0804871-1 and br 10 2012 009901-2) twice a week for eight weeks, while the control group will receive passive muscle stretching and maintained their usual routine during the same period. both groups will be assessed at baseline and immediately after the intervention protocol. finally, a follow-up evaluation will be performed 8 weeks after the protocol ending (to verify possible long-lasting effects of this exercise protocol).

Eligibility criteria:
inclusion criteria: * subjects able to go to training or assessment places; * subjects that are agreement with the study protocol and sign the ; * subjects in stage i, ii or iii of parkinson disease according to the hoehn and yahr scale. exclusion criteria: * subjects do not keep their usual routine (apart of the research protocol); * subjects with physical or functional limitations that prevent the assessment test battery; * subjects with heart or lung diseases that prevent the exercise performance; * subjects with cancer; * subjects with major visual deficits; * subjects with recurrent vertigo; * subjects with uncontrolled systemic blood pressure.

Keywords: balance mobility trunk control
study on the frequency of de novo atrial fibrillation in septic shock in medical intensive care

Conditions: Septic Shock; Atrial Fibrillation

Summary: the aim of this pilot study is to determine, as exhaustively as possible thanks to the continuous and precise recording of heart rhythm, the frequency of de novo atrial fibrillation in septic shock, which is currently unknown, and to identify specific factors that could be associated with the condition. these will be investigated more precisely in a future study. this constitutes the first step in a reflection on the management of cardiac arrhythmia by atrial fibrillation (acfa) in septic shock in medical intensive care, known as a major prognostic factor for morbimortality, but for which management is uncertain in the absence of reference data.


Eligibility criteria:
inclusion criteria: * all patients in septic shock (defined as hypotension that is not reversed by fluid resuscitation and requires the use of vasopressor agents) hospitalized in medical intensive care * patients with national health insurance cover * age: at least 18 years with no upper limit exclusion criteria: * transferred from another intensive care unit for septic shock * adults under guardianship * history of atrial fibrillation
single ascending dose study of sar443820 in healthy adult chinese and japanese female and male participants

Conditions: Multiple Sclerosis Healthy Subjects

Summary: primary objective: to assess the pharmacokinetic parameters of sar443820 after ascending single oral doses in healthy east asian (chinese and japanese) adult participants. secondary objective: to assess the tolerability and safety of sar443820 after ascending single oral doses in healthy east asian (chinese and japanese) adult participants

the duration of the study for a participant will be up to approximately 7 weeks and include: * screening period: up to 4 weeks (day -28 to day -2). * institutionalization period at each period of treatment: 4 days (day -1 to day 3, single sar443820 administration on day 1). * wash-out period: at least 5 days between each dosing. * end-of-study visit: period 3/ day 6±1 day.

Eligibility criteria:
inclusion criteria: east asian (chinese and japanese) male and/or female participant must be 20 to 55 years of age inclusive, at the time of signing the informed consent. chinese or japanese ethnicity, according to the following criteria: chinese; born in china or ethnic chinese born outside of china, and a descendent of 4 ethnic chinese grandparents who were all born in china. japanese; born in japan or ethnic japanese born outside of japan, and a descendent of 4 ethnic japanese grandparents who were all born in japan. participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ecg. body weight within 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, and body mass index (bmi) within the range 18.0 and 30.0 kg/m2, inclusive. exclusion criteria: medical history of any seizure. any medication (including st john's wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, any live attenuated vaccine given within 3 months or any non-live vaccine given within 2 weeks before inclusion, and any biologics (antibody or its derivatives) given within 4 months before inclusion. positive severe acute respiratory syndrome coronavirus 2 (sars-cov-2) test. current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the columbia-suicide severity rating scale \[c-ssrs\]), or a lifetime suicide attempt. a "yes" response to questions 4 or 5 on the suicidal ideation section, or a score of 4 or 5 on the intensity of ideation section of the baseline/screening version of the c-ssrs at screening, or on the since last visit version of the c-ssrs at baseline. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial
a dose-response evaluation of alk (the sponsor) tree allergy immunotherapy tablet

Conditions: Birch Pollen Allergy

Summary: the primary aim of this trial is to evaluate the dose-response relationship for the alk tree ait administered once daily in order to define a dose-range that would be suitable for at-home administration.


Eligibility criteria:
inclusion criteria: * a history of moderate to severe birch pollen allergy * use of symptomatic medication for treatment of birch pollen allergy * positive skin prick test to birch extract * positive specific ige against bet v 1 exclusion criteria: * overlapping perennial allergies * history of uncontrolled asthma within the last 3 months * fev1 \< 70% of predicted value in adults or fev1 \< 80% of predicted value in adolescents * previous or ongoing treatment with immunotherapy
a study of lymphangiogenesis in colorectal and nasopharyngeal cancer

Conditions: Colorectal Cancer; Nasopharyngeal Cancer

Summary: 1. to determine the association between lvd and clinico-pathologic variables in archived colorectal cancer and nasopharyngeal carcinoma specimens 2. to determine the association between vegf-c,-d expression with cox-2 expression and clinico-pathologic variables in colorectal cancer and nasopharyngeal carcinoma 3. to determine the effect of celecoxib on lymphangiogenesis in nasopharyngeal carcinoma lymphangiogenesis and factors modulating lymphangiogenesis are associated with clinico-pathological outcome in nasopharyngeal carcinoma and colorectal cancer. celecoxib down-regulates lymphangiogenesis archival colorectal cancer and nasopharyngeal carcinoma tumor specimens will be obtained from the department of pathology. to determine the effect of celecoxib on lymphangiogenesis in nasopharyngeal carcinoma, the investigators intend to analyze archived specimens collected in a previously conducted study. colorectal tumor and nodal specimens and nasopharyngeal carcinoma primary will be examined for mvd, lvd and growth factor expression using established haematoxylin and eosin and immunohistochemical techniques. quantification of lvd and mvd shall be performed by two pathologists blinded to clinico-pathological variables using standardised methods.


Eligibility criteria:
inclusion criteria: * male and female patients are eligible * patients 21 years or older exclusion criteria: * none
study on the effect of a beta blocker on increased sensitivity to pain in humans caused by opioids

Conditions: Hyperalgesia

Summary: this research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. in a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. the goal of this study is to identify a possible inhibitor of this phenomenon.

recent evidence suggests that opioid therapy may cause a biphasic response, i.e. initial pain relief followed paradoxically by a longer lasting hypersensitivity to pain. recent genetic analysis in mice suggests that beta adrenergic receptor antagonists reduce opiate-induced hyperalgesia (oih). the purpose of this study is to determine the analgesic and antihyperalgesic properties of the beta-blocker propranolol on remifentanil-induced hypersensitivity in humans. the investigators want to determine the analgesic and antihyperalgesic properties of the beta-blocker propranolol on remifentanil-induced hypersensitivity in humans. the investigators hope to learn whether the administration of beta-blocker propranolol will significantly diminish the hyperalgesic response after administration of an opioid. the primary outcome measure for this study is change in size (area) of secondary hyperalgesia after cessation of remifentanil infusion, a measure of oih.

Eligibility criteria:
inclusion criteria: 1. healthy men, 2. age between 18 and 45 years 3. normal weight (according to the table provided by metropolitan life insurance). exclusion criteria: 1. hypersensitivity to opioids or naloxone, 2. history of addictive disease, 3. significant cardiac, respiratory, gastrointestinal, neurological, dermatological, and psychiatric diseases, 4. concurrent medication with an analgesic drug, 5. student and employees affiliated with our laboratory
trial of steroid avoidance and low-dose cni by atg-induction in renal transplantation

Conditions: Diabetes Mellitus

Summary: balancing immunosuppressive treatment in organ transplantation in order to achieve effective prevention of rejection on one side and avoidance of negative side effects on the other side is a major challenge, leading to developing different immunosuppressive protocols. cornerstones of immunosuppressive treatment such as corticosteroids (cs) and calcineurin inhibitors (cni) are known to cause an increased incidence of diabetes, cardiovascular morbidity, nephrotoxicity and malignancies. the investigators believe that both avoidance of cs and minimization of cni, while using anti-thymocyteglobuline(atg) induction (instead of interleucin-2 receptor blockers) and mycofenolate mofetil(mmf) therapeutic drug monitoring is going to reduce negative side effects, without increased rejection frequency in renal transplanted patients.


Eligibility criteria:
inclusion criteria: * first or second single kidney (cadaveric or living donors) transplant recipients. * considered for a standard immunosuppressive protocol. * must be capable of giving written informed connect for participation in the study for 24 months. exclusion criteria: * diabetes mellitus or plasma glucose \>11,1 at admission. * receiving steroids at the time of transplantation or likely to need steroids after transplantation. * multiorgan transplants and/or previously transplanted with any other organ than kidney. * panel reacting antibodies(pra) \>25% in most recent test or considered to be of high risk for rejection which requires an enhanced immunosuppression. * renal transplants from hla-identical sibling. * hypersensitivity to, or disability to take immunosuppressive drugs. * blood group(abo)-incompatible transplants. * unlikely to comply with the study requirements. * transplant from donor positive for hiv, hbsag, hepatitis c. * female of childbearing potential planing/being pregnant or unwilling to use contraception.

Keywords: nodat renal transplantation corticosteroids avoidance cni minimization
screening of helicobacter pylori in children of positive infected mothers

Conditions: H Pylori Infection

Summary: helicobacter pylori is aspiral shaped gram negative organism that colonized the gastric mucosa.it was showen that intra familial infection play role in transmission of h pylori and mother play the key role in transmission .

prevelance of h pylori infection in children whose mother positive infected is different according to risks factors such as mother education,work out side or not , socioeconomic status, family size and breast feeding or not.h pylori in children can be represent with recurrent abdominal pain ,recurrent diarrhea,repeated vomitting ,pallor ,fulness,non variceal hematemesis,loss of appetite,reterded growth.complication of h pylori include gastric ulcer,duodenal ulcer,gastric atrophy may lead to gastric cancer and intestinal metaplasia.

Eligibility criteria:
inclusion criteria: child with dyspeptic symptoms exclusion criteria: malnutrition childs patient with metabolic disorder
evaluation of clinical performance and usability of istatis covid-19 ag rapid test at poc

Conditions: COVID-19 Virus Infection; COVID-19; Coronavirus Disease-19; COVID-19 Pandemic; SARS-CoV-2 Infection

Summary: a rapid point of care test for the detection of virus particles will be compared to the fda approved eua rt-pcr detection standard. the istatis covid-19 ag rapid test is intended for rapid point-of-care detection of the sars-cov-2 nucleocapsid protein antigen.

primary objective: to evaluate the clinical performance of istatis covid-19 antigen test by untrained operators at point of care settings that meet requirements for clia waived tests. secondary objective: to evaluate the performance of istatis covid-19 antigen test around limit of detection samples will be collected in clia waived settings from approximately 200 subjects who present with or are referred for concerns about sars-cov-2. the goal is to collect a minimum of n=30 confirmed covid-19 positive subjects and n=30 confirmed covid-19 negative subjects of comparable ages, genders, and races. individual participation only includes sample collection and 1 day visit for the purpose of study

Eligibility criteria:
inclusion criteria: * participant is willing to sign verbal informed consent form * age 18 or older * subject is suspected case of covid-19 by clinical criteria: a patient with acute respiratory tract infection (sudden onset of at least one of the following: cough, fever, shortness of breath, fatigue, decreased appetite, myalgia) * subjects with above mentioned symptom onset within the 7 days * participant is willing to provide two swabs - one anterior nasal swab sample for istatis test and another nasopharyngeal or nasal swab sample for comparator rt-pcr testing exclusion criteria: * individuals who presented with 8 or greater days of covid- 19 related symptoms, (fever, cough, fatigue, decreased appetite, shortness of breath, myalgia) or postdefervescence and/or convalescence * any reason as identified by the principal investigator at the participating site that could disqualify the subject from participation. the reason for exclusion was documented * subject withdraw consent

Keywords: diagnostic kit diagnostic devices lateral flow device test
idiopathic pre-capillary pulmonary hypertension in eskd patients

Conditions: Pulmonary Hypertension

Summary: this study investigates the prevalence and prognosis of idiopathic pre-capillary pulmonary hypertension (ph) in patients with end-stage kidney disease (eskd).

pulmonary hypertension (ph) is a rare cardiovascular disease with progressive and fatal features. ph is classified into the 5 groups, and the prevalence of group 1 pulmonary arterial hypertension, including idiopathic and heritable, is 5 to 15 cases per one million adults and a median survival was reportedly three years. ph found in patients with end-stage kidney disease (eskd) is classified into group 5, because the pathogenesis and clinical characteristics have not been clarified. the prevalence of ph in patients with eskd was reportedly around 17\~56% based on echocardiographic studies. in this study, we evaluated the incidence of idiopathic pre-capillary ph of eskd patients by right heart catheterization, and examined the prognosis by following the occurrence of heart failure death.

Eligibility criteria:
inclusion criteria: * symptoms of dyspnea, hypotension (systolic blood pressure \<90mmhg, or syncope. * systolic pressure gradients in tricuspid valve of 40 mmhg or more. * in right heart catheterization, precapillary ph was defined as mean pulmonary arterial pressure (pap) ≥25 mmhg, pulmonary vascular resistance (pvr) ≥3 wood unit, and pulmonary artery wedge pressure (pawp) ≤15 mmhg. exclusion criteria: * patients with systolic left ventricular dysfunction (left ventricular ejection fraction \[lvef\] \<50%), mitral or aortic regurgitation of grade 2 or more, aortic or mitral surface \<1.5 cm2, severe anemia (blood hemoglobin \<9 g/dl), severe chronic obstructive pulmonary disease defined by percent predicted forced expiratory volume in one second \<60%, or lung fibrosis were not enrolled in this study. * in right hear catheterization, pap ≥25 mmhg and pawp \>15 mmhg were diagnosed as post capillary ph.

Keywords: heart failure survival end-stage kidney disease
electrical stimulation for the relief of freezing of gait (fog) in parkinson's patients

Conditions: Parkinson's Disease

Summary: potential for electrical stimulation to ameliorate freezing of gait (fog)

the purpose of this study is to investigate the potential for an electrical stimulation intervention to ameliorate freezing of gait (fog) and related gait disturbances in parkinson's patients.

Eligibility criteria:
inclusion criteria: * a diagnosis of idiopathic parkinson's disease (pd) (uk, pd brain bank criteria) * a hoehn and yahr stage of 2 - 4 * exhibiting freezing of gait or another gait abnormality in the on state. * an ability to mobilise independently with or without a walker or walking cane for the purpose of research when in the 'on' state exclusion criteria: * a serious cognitive impairment (mmse\<24) * pregnant or currently involved in another clinical trial. * pacemakers * on opioid or neuropathic pain medication

Keywords: freezing of gait gait comfort pain tolerance pain sensory threshold motor threshold pain threshold
children with diabetes at risk for heart disease.

Conditions: Diabetes Mellitus, Type 1; Diabetes Complications

Summary: patients with type 1 diabetes type 1 (dm1) have increased risk of death due to heart disease and stroke. these cardiovascular conditions (cvd) are the leading cause of death in patients with dm1 younger than 40 years of age and up to 35% of all persons with dm1 will die before age 55 from cvd. strategies are needed to help identify adolescents with dm1 at risk for cvd so that interventions to prevent heart disease and stroke can be undertaken.

patients with type 1 diabetes and healthy controls will have evaluation of their lipid profile. arterial stiffness, heart rate variability and adiposity measurements will be done in patients with type 1 diabetes and healthy controls. blood pressure and heart rate will be recorded. 50 ml of urine will be collected from patients and controls. all studies will be performed as a single outpatient visit at georgetown university.

Eligibility criteria:
inclusion criteria: diabetes type 1 or healthy exclusion criteria: taking medications that lower cholesterol duration of type 1 diabetes \< 1 year.

Keywords: children cholesterol